American Century Companies Inc. Trims Stake in Xenon Pharmaceuticals Inc. $XENE

American Century Companies Inc. lessened its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 3.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 659,257 shares of the biopharmaceutical company’s stock after selling 20,600 shares during the quarter. American Century Companies Inc. owned about 0.85% of Xenon Pharmaceuticals worth $26,469,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Holocene Advisors LP acquired a new position in shares of Xenon Pharmaceuticals in the second quarter worth $56,637,000. Geode Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after acquiring an additional 900,746 shares during the last quarter. Braidwell LP boosted its stake in shares of Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after acquiring an additional 895,154 shares during the last quarter. Vestal Point Capital LP increased its position in Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after purchasing an additional 700,000 shares in the last quarter. Finally, Commodore Capital LP increased its position in Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.07% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Trading Down 0.3%

Xenon Pharmaceuticals stock opened at $41.94 on Monday. The stock has a fifty day moving average price of $42.25 and a 200 day moving average price of $41.24. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.99. The firm has a market capitalization of $3.49 billion, a P/E ratio of -9.62 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the business earned ($0.84) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on XENE. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. lifted their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Needham & Company LLC boosted their price objective on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, Wells Fargo & Company upped their price objective on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $55.50.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.